Quantcast

Industry news that matters to you.  Learn more

Edimer Pharmaceuticals Presents Study Results on Non-Invasive Sweat Gland Analysis as a Biomarker in XLHED Patients

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced key findings of a study exploring novel approaches to the assessment of sweat function in males with XLHED. Affected individuals lack a normal sweat response, placing them at life-long risk for clinically-significant hyperthermia. The study reported on the use of non-invasive technologies for quantitative sweat function, and correlated these results with the nature and location of ectodysplasin A (EDA) gene defects associated with XLHED. Data analysis confirmed a consistent, quantifiable defect in sweat gland function as a disease biomarker in XLHED patients, even in the setting of normal sweat pore counts. The study outcomes were reported at the 60th Annual Meeting of the American Society of Human Genetics (ASHG) in Washington, D.C.

Discovery and Validation of 13 Diabetes Biomarkers to be Commercialized

After three years of collaborative research involving patients from The Busselton Health Study, drug discovery company Proteomics International announced the identification and analytical validation of 13 protein biomarkers for a significant complication of diabetes – diabetic nephropathy (kidney disease). In a presentation at the Human Proteome Organisation’s World Congress in Sydney, Australia, Dr Richard Lipscombe, Managing Director of Proteomics International, revealed the findings that could benefit many of the 250 million people worldwide who have diabetes.

Prometheus, Tarrot to Seek Crohn’s Disease Biomarkers for PGx Applications

Prometheus Laboratories and Tarrot Laboratories today announced an exclusive research collaboration and license agreement to identify biomarkers associated with clinical response to anti-TNF therapies in Crohn’s disease.

BioSystems International Merges with MicroBioChips

Biosystems International (BSI), a biotechnology company specializing in the discovery of novel monoclonal antibody based diagnostics, announces its merger with the company MicroBioChips (MBC) by contribution of assets.